Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This study is not being conducted in the United States.
Patients who are intolerant of topical corticosteroids (TCS) have either experienced an
adverse event resulting from the use of TCS, or require unacceptable levels of exposure to
TCS in order to control their AD. This is of particular concern for patients with recurrent
flares on delicate skin areas such as the head and neck.
The purpose of this study is to investigate whether pimecrolimus cream 1%, a non-steroidal
anti-inflammatory drug, is efficacious in treating mild to moderate head and neck AD in
patients who are intolerant of, or dependent on topical corticosteroids.